Wilms Tumor 1 (WT1) (N-Term) Peptide
WT1
Reactivity: Human
Host: Synthetic
WB, BP
Catalog No. ABIN986234
Quick Overview for Wilms Tumor 1 (WT1) (N-Term) Peptide (ABIN986234)
Target
WT1
(Wilms Tumor 1 (WT1))
Origin
Human
Source
Synthetic
Application
Western Blotting (WB), Blocking Peptide (BP)
-
-
Protein Region
- N-Term
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-WT1 antibody (Catalog #: ARP37988_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- WT1 (Wilms Tumor 1 (WT1))
-
Background
-
WT1 is a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors. Multiple transcript variants, resulting from alternative splicing at two coding exons, have been well characterized. There is also evidence for the use of non-AUG (CUG) translation initiation site upstream of, and in-frame with the first AUG, leading to additional isoforms.This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors. Multiple transcript variants, resulting from alternative splicing at two coding exons, have been well characterized. There is also evidence for the use of non-AUG (CUG) translation initiation site upstream of, and in-frame with the first AUG, leading to additional isoforms. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.
Alias Symbols: AWT1, GUD, WAGR, WIT-2, WT33, NPHS4, EWS-WT1
Protein Interaction Partner: AREG,CIAO1,CREBBP,FHL2,PAWR,PAX2,PRKACA,TP53,TP63,TP73,U2AF2,UBE2I,WTAP,WTIP,PAWR,Pawr,TP53,U2AF2,UBE2I,WTAP
Protein Size: 514 -
Molecular Weight
- 56 kDa
-
Gene ID
- 7490
-
NCBI Accession
- NM_000378, NP_000369
-
UniProt
- E9PMK7
Target
-
You are here:
